Brief intro:
- Author: Chunli Zhao, Zijing Yang, Zhongrui Chen, Wenqi Liang, Shusheng Gong, and Zhengde Du
- Journal: Mol Med
- Doi: https://www.doi.org/10.1186/s10020-022-00552-y
- Publication Date: 2022 Oct 20
Products/Services used in the paper
Quotation shows PackGene:Te AAV-ie vector carrying UCP2, or empty vector with a CAG promoter and enhanced green fuorescent protein (AAV-ie-CAG-UCP2-eGFP or AAV-ie-CAG-eGFP), were manufactured by PackGene Biotech (Guangzhou, China). AAV-ie-CAG-eGFP was as control vector.
Research Field:ear
AAV Serotype:AAV-ie
Targeted organ:inner ear
Animal or cell line strain:Male C57BL/6 J mice
Abstract
Uncoupling protein 2 (UCP2), activated by excessive reactive oxygen species (ROS) in vivo, has the dual effect of reducing ROS to protect against oxidative stress and reducing ATP production to regulate cellular metabolism. Both the UCP2 and ROS are increased in cochleae in age-related hearing loss (ARHL). However, the role of UCP2 in sensory hair cells in ARHL remains unclear.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
